يعرض 1 - 10 نتائج من 27 نتيجة بحث عن '"Afshari, Daryoush"', وقت الاستعلام: 0.99s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية

    المصدر: Caspian Journal of Neurological Sciences; Autumn2023, Vol. 9 Issue 4, p220-228, 9p

    مصطلحات موضوعية: VALPROIC acid, MIGRAINE, LIVER function tests, BLOOD cell count

    مصطلحات جغرافية: KERMANSHAH (Kermanshahan, Iran)

    مستخلص: Background: Sodium valproate is recommended as a first-line drug to prevent migraine attacks, and sodae is an herbal medicine. Objectives: Sodium valproate and herbal sodae were compared for effectiveness and side effects. Materials & Methods: A two-center, randomized, double-blind clinical trial included migraine patients from Kermanshah and Hamadan cities into two groups: Sodae herbal recipients and valproate (200 mg) recipients, for 3 months. A numerical rating scale (NRS) scale was used to measure residual pain at the end of each month of treatment. Also, a researcher-made form and the headache impact test (HIT-6) questionnaire were used. Side effects reported by the patients were collected, and liver function tests and complete blood cell count tests were conducted. Results: A total of 70 migraine patients were evaluated: 33 patients (47%) in the soda group and 37 patients (53%) in the valproate group. The NRS scores in both groups decreased constantly, with no significant difference (P=0.303). Also, HIT-6 scores were constantly reduced in both groups with no significant difference (P>0.05). More side effects are significantly (P=0.043) reported in the valproate group (54.05%) than in the sodae group (30.30%). The most common side effect in the valproate group was drowsiness (13.5%), while among the sodae group, it was diarrhea (15.1%). Conclusion: The sodae and valproate did not differ in headache improvement, HIT-6 scores, and changes in laboratory parameters. However, the valproate group reported more side effects than the sodae group. Sodae is a suitable herbal medicine for preventing and controlling migraine attacks. [ABSTRACT FROM AUTHOR]

    : Copyright of Caspian Journal of Neurological Sciences is the property of Negah Institute for Social Research & Scientific Communication and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

  5. 5
    دورية أكاديمية
  6. 6
    دورية أكاديمية
  7. 7
    دورية أكاديمية
  8. 8
    دورية أكاديمية
  9. 9

    المصدر: Neurosciences

    الوصف: Objective: To evaluate the efficacy and safety of carbamazepine, pregabalin, and venlafaxine in patients with painful diabetic neuropathy (PDN). Methods: Our study was performed as a randomized, double-blind, parallel-group clinical trial between December 2012 and December 2013 at Kermanshah University of Medical Sciences, Kermanshah, Iran. Two hundred and fifty-seven patients with clinically definite PDN were randomized to receive, carbamazepine, venlafaxine, or pregabalin. The primary outcome was subjective pain as assessed by the visual analogue scale (VAS). Secondary outcomes consisted of sleep, mood, and work interference assessments, and a percentage of patients achieving at least 50% reduction in pain intensity. Results: Means of VAS scores for carbamazepine, pregabalin, and venlafaxine treatment groups at the baseline (74.5, 82.3, and 74.5) and endpoint (39.6, 33.4, and 46.6) revealed significant reduction, although pregabalin was more efficacious than carbamazepine, and venlafaxine. Improvements in means scores of sleep, mood, and work interferences were identified in all treatment groups. Conclusion: This study showed the efficacy of venlafaxine, pregabalin, and carbamazepine in pain reduction in patients with diabetic neuropathy, although pregabalin was shown to be superior to carbamazepine, and venlafaxine in relieving pain, no significant superiority was shown between carbamazepine, and venlafaxine.

  10. 10
    دورية أكاديمية